Shares of Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), a biopharmaceutical company engaged in the development and commercialization of products to treat diseases associated with inflammation, continued to rally in trading today.
ANTH shares ended the day 20.30% higher at $1.60 on above average volume of 25.20 million. The stock has now gained 127.27% in the last three trading sessions.
The rally in ANTH shares was sparked after the company on Monday announced the final set of clinical data from the Phase 2b PEARL-SC Study in patients with systemic lupus erythematosus. ANTH said that final data from the PEARL-SC clinical study with 200 mg weekly blisibimod suggest sustained and greater treatment effects compared to placebo.
Colin Hislop, MD, Anthera’s Chief Medical Officer, said that the results continue to validate the importance of phase 2 studies to identify the appropriate patient, dose and endpoint in order to optimize phase 3 study design.
Recent Comments